Hold Sudeep Pharma: target of Rs 1100: ICICI Securities

Moneycontrol • 2 days ago

Original source

Key Investment Pillars

  • PFN segment growth: Sudeep Pharma's PFN segment revenue grew 57.5% YoY, driven by higher volumes and pass-through of raw material costs, with EBITDA margin expansion to 40.8%.
  • Battery materials business: The company's battery-grade iron phosphate project is on track for commercial operations in Apr'27, with strong demand visibility and potential for premium pricing.
  • Specialty ingredients segment recovery: The segment's revenue is expected to grow in H2FY27, supported by new customer contracts and approvals, with potential for margin recovery.

Thesis Validation Checklist

  • Watch for: PFN segment growth sustainability, battery materials business execution, and specialty ingredients segment recovery, as well as EBITDA margin expansion and working capital management.
  • Key signals: Commercial supplies commencement from the Dahej facility, customer validation, and offtake agreements for battery materials, as well as new customer contracts and approvals for specialty ingredients.
  • Risks: Underwhelming volume performance, delays in launching new products, limited success in battery chemicals, and pressure on gross and EBITDA margins due to competitive intensity or demand weakness.